Dyne Therapeutics (NASDAQ:DYN) Posts Quarterly Earnings Results, Misses Expectations By $0.25 EPS

Dyne Therapeutics (NASDAQ:DYN) announced its quarterly earnings data on Tuesday. The company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25), Zacks reports.

Dyne Therapeutics Trading Up 11.9 %

NASDAQ:DYN traded up $3.49 during trading hours on Wednesday, hitting $32.82. 444,100 shares of the company were exchanged, compared to its average volume of 1,486,979. The stock has a market capitalization of $3.30 billion, a price-to-earnings ratio of -8.78 and a beta of 1.10. Dyne Therapeutics has a one year low of $9.26 and a one year high of $47.45. The company has a fifty day simple moving average of $32.63 and a 200 day simple moving average of $35.12.

Insider Activity

In other Dyne Therapeutics news, Director Dirk Kersten sold 79,411 shares of the firm’s stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $36.45, for a total transaction of $2,894,530.95. Following the completion of the transaction, the director now owns 234,127 shares in the company, valued at approximately $8,533,929.15. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, SVP Richard William Scalzo sold 1,390 shares of the firm’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $34.55, for a total transaction of $48,024.50. Following the completion of the sale, the senior vice president now owns 98,568 shares of the company’s stock, valued at $3,405,524.40. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Dirk Kersten sold 79,411 shares of the business’s stock in a transaction on Friday, September 20th. The shares were sold at an average price of $36.45, for a total transaction of $2,894,530.95. Following the transaction, the director now owns 234,127 shares in the company, valued at $8,533,929.15. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 158,975 shares of company stock valued at $5,693,789. Company insiders own 20.77% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on DYN shares. HC Wainwright reiterated a “buy” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a research note on Wednesday. JPMorgan Chase & Co. cut Dyne Therapeutics from an “overweight” rating to a “neutral” rating and decreased their target price for the company from $43.00 to $35.00 in a research report on Thursday, October 24th. Guggenheim increased their target price on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, August 15th. Oppenheimer reaffirmed an “outperform” rating and set a $55.00 price target on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. Finally, Stifel Nicolaus increased their price objective on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a research note on Friday, August 16th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $50.60.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.